Modality
Peptide
MOA
ALKi
Target
FGFR
Pathway
Complement
MSLGS
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
→ Dec 2029
Phase 1Current
NCT08463615
340 pts·MS
2021-10→2029-12·Recruiting
NCT08374226
1,649 pts·MS
2019-10→2029-08·Active
1,989 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-043.3y awayPh2 Data· MS
2029-12-213.7y awayPh2 Data· MS
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2029-08-04 · 3.3y away
MS
Ph2 Data
2029-12-21 · 3.7y away
MS
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08463615 | Phase 1/2 | MS | Recruiting | 340 | EFS |
| NCT08374226 | Phase 1/2 | MS | Active | 1649 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |